Domino Printing provided live demonstrations of their latest laser technology innovations, plus their partnerships with Omega Design and 3C! Packaging to help healthcare companies address strict packaging requirements at the International Pharmaceutical Expo (INTERPHEX) in New York City’s Javits Center April 21-23.
At Booth #2240, Domino Business Development Manager Mark Shaffer led a discussion and demonstration to showcase the abilities of their new F220i Fiber Laser. Ideal for pharmaceutical and medical device packaging, both printers feature laser technology with the flexibility to print permanent high-quality codes on a variety of materials to meet strict industry requirements, such as guidelines placed by the Drug Quality and Security Act (DQSA) and the FDA’s Unique Device Identification (UDI) system.
“We feel strongly that we need to understand the regulations and requirements of current and future legislation to ensure that we are a valued partner to our customers,” Shaffer explained. “This industry knowledge also allows us to tailor our solutions to meet current and future requirements.”
Tailored solutions, such as Domino’s new F220i Fiber Laser, are designed to meet the challenges currently facing the healthcare industry. Designed to code materials that typically aren’t suitable for CO2 laser technology—such as metals, plastics and certain films—the F220i Fiber Laser broadens the range of products that can be marked. This new flexibility is particularly important to the medical device sector, as many companies seek solutions to comply with the FDA’s UDI system which, over the next seven years, will require all medical devices to be labeled with human and machine readable identifiers through distribution and use.
Domino’s partnerships with 3C! Packaging and Omega Design demonstrate the value of combining unique technologies and expertise to meet the challenges of serialization, Shaffer explains. “This is an exciting time in the life sciences sector. Impending regulations such as DQSA and UDI are driving a flurry of compliance activity in both Pharma and Medical Devices,” he stated. “These are fixed timelines that aren’t changing. Couple that with similar global regulations in Europe and other parts of the world, and you’ll see it’s more important than ever to work with partners that are well-versed in the regulations, global in scope to scale solutions across the world, and are well-respected by both end users and the OEM partners.”
